The PNPLA6 Family: Understanding the Spectrum
At a Glance
Laurence-Moon syndrome belongs to a broader PNPLA6-related disorder spectrum. Historical labels such as Boucher-Neuhäuser, Gordon-Holmes, Oliver-McFarlane, and SPG39 describe overlapping patterns, so care should be guided by each person’s symptoms and screening needs.
When you receive a diagnosis of Laurence-Moon syndrome, it is natural to focus heavily on that specific name. However, modern genetics has revealed that your condition is part of a larger “family” of overlapping conditions known as PNPLA6-associated disorders [1][2].
Think of the PNPLA6 gene as creating a continuous spectrum of symptoms. Because these conditions overlap so much, the boundaries between them are not strict, and many people have “hybrid” or atypical features that don’t perfectly fit into one historical box [3].
The PNPLA6 “Family” of Syndromes
There are five main historical labels that doctors used to think were separate diseases but are now known to be different presentations of the same genetic spectrum [1][4].
1. Boucher-Neuhäuser Syndrome (BNS)
This presentation classically involves a “triad” of symptoms: ataxia (balance issues), chorioretinal dystrophy (vision loss), and hypogonadotropic hypogonadism (hormonal/puberty issues) [5][6].
2. Gordon-Holmes Syndrome (GHS)
In this version of the spectrum, balance issues (ataxia) and hormonal issues are prominent [7]. Some people with GHS may have mild or highly variable vision loss [8].
3. Oliver-McFarlane Syndrome (OMS)
OMS often appears very early in life. It is frequently distinguished by unique physical features like trichomegaly (unusually long, thick eyelashes and eyebrows) and sparse hair on the head [9][10]. It also commonly involves short stature and multiple deficiencies in pituitary hormones [11].
4. Spastic Paraplegia Type 39 (SPG39)
This label focuses primarily on nerve symptoms in the legs, causing spasticity (stiffness) and weakness that can make walking difficult [1][12]. Some patients may only have leg issues, while others eventually develop vision or hormonal symptoms [12].
5. Laurence-Moon Syndrome (LMS)
This label typically describes a combination of vision loss, ataxia, spasticity, and hormonal changes, though the exact mix and severity of these features vary from person to person [1][4].
Comparing the Typical Features
| Feature | Laurence-Moon | Boucher-Neuhäuser | Gordon-Holmes | Oliver-McFarlane | SPG39 |
|---|---|---|---|---|---|
| Vision Loss | Common | Common | Variable | Common | Variable |
| Balance (Ataxia) | Common | Common | Common | Variable | Variable |
| Leg Stiffness | Common | Variable | Variable | Not typical | Common |
| Hormone Issues | Common | Common | Common | Common | Variable |
| Long Lashes | Not typical | Not typical | Not typical | Common | Not typical |
Note: This table reflects typical historical descriptions. Because this is a continuous spectrum, an individual may experience symptoms outside these historical boundaries.
Why the Spectrum Concept Matters to You
It can be frustrating when different doctors use different names or simply write “PNPLA6-related disorder” in your chart. However, understanding that you are on a spectrum is important for your care:
- Symptoms Guide Management: While your specific genetic diagnosis is crucial for counseling and screening, day-to-day management follows your actual symptoms [2]. If you have balance issues, your care team will focus on physical therapy regardless of whether the historical label is GHS or LMS.
- Predictive Screening: Knowing the other syndromes in the family helps your doctor know what to look for. For example, since Oliver-McFarlane involves growth hormone and adrenal issues, your endocrinologist will know to periodically evaluate you for broader pituitary deficiencies [11][13].
- A Shared Community: You are not just a “Laurence-Moon patient”; you are part of a larger community of people with PNPLA6-related disorders. This opens up more opportunities for support groups, registries, and research that cover the entire spectrum [1].
Common questions in this guide
What is the PNPLA6-related disorder spectrum?
How is Laurence-Moon syndrome related to the other PNPLA6 syndromes?
What symptoms can occur with Laurence-Moon syndrome?
Why might someone with a PNPLA6 diagnosis need hormone screening?
Does the historical label determine treatment for Laurence-Moon syndrome?
Get notified when new evidence is published on Laurence-Moon syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (13)
- 1
PNPLA6 disorders: what's in a name?
Liu J, Hufnagel RB
Ophthalmic genetics 2023; (44(6)):530-538 doi:10.1080/13816810.2023.2254830.
PMID: 37732399 - 2
Neuropathy target esterase activity defines phenotypes among PNPLA6 disorders.
Liu J, He Y, Lwin C, et al.
Brain : a journal of neurology 2024; (147(6)):2085-2097 doi:10.1093/brain/awae055.
PMID: 38735647 - 3
Neuropathy target esterase activity predicts retinopathy among PNPLA6 disorders.
Liu J, He Y, Lwin C, et al.
bioRxiv : the preprint server for biology 2023; doi:10.1101/2023.06.09.544373.
PMID: 37333224 - 4
Multifaceted and Age-Dependent Phenotypes Associated With Biallelic PNPLA6 Gene Variants: Eight Novel Cases and Review of the Literature.
Nanetti L, Di Bella D, Magri S, et al.
Frontiers in neurology 2021; (12()):793547 doi:10.3389/fneur.2021.793547.
PMID: 35069422 - 5
A novel PNPLA6 compound heterozygous mutation identified in a Chinese patient with Boucher‑Neuhäuser syndrome.
Zheng R, Zhao Y, Wu J, et al.
Molecular medicine reports 2018; (18(1)):261-267 doi:10.3892/mmr.2018.8955.
PMID: 29749493 - 6
Novel variants in PNPLA6 causing syndromic retinal dystrophy.
Wu S, Sun Z, Zhu T, et al.
Experimental eye research 2021; (202()):108327 doi:10.1016/j.exer.2020.108327.
PMID: 33141049 - 7
Different Cerebellar Ataxia Phenotypes Associated with Mutations of the PNPLA6 Gene in Brazilian Patients with Recessive Ataxias.
Teive HAG, Camargo CHF, Sato MT, et al.
Cerebellum (London, England) 2018; (17(3)):380-385 doi:10.1007/s12311-017-0909-y.
PMID: 29248984 - 8
Retinal Pigment Epithelial Changes in Gordon Holmes Syndrome.
Lu ES, Kozek LK, Martinez-Velazquez L, et al.
Journal of vitreoretinal diseases 2026; 24741264261442895 doi:10.1177/24741264261442895.
PMID: 42137175 - 9
Oliver McFarlane syndrome: two new cases and a review of the literature.
Lisbjerg K, Andersen MKG, Bertelsen M, et al.
Ophthalmic genetics 2021; (42(4)):464-473 doi:10.1080/13816810.2021.1904419.
PMID: 33818269 - 10
Case Report: Novel compound heterozygous mutations in PNPLA6 gene associated with Oliver-McFarlane syndrome.
Zheng J, Wang Z, Li K, et al.
Frontiers in genetics 2025; (16()):1660243 doi:10.3389/fgene.2025.1660243.
PMID: 41282473 - 11
New insights into Oliver-McFarlane syndrome: adrenocortical hypofunction and variable expressivity in a Chinese sibling pair.
Du C, Yu T, Liu S, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2026; (39(6)):622-627 doi:10.1515/jpem-2025-0731.
PMID: 41846525 - 12
A novel PNPLA6 mutation in a Turkish family with intractable Holmes tremor and spastic ataxia.
Emekli AS, Samanci B, Şimşir G, et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(4)):1535-1539 doi:10.1007/s10072-020-04869-6.
PMID: 33210227 - 13
Novel PNPLA6 Variants: Hypogonadotropic Hypogonadism, Pituitary Hypoplasia, Anosmia, and Cerebellar Atrophy in Siblings.
Hussain MA, Kumar V, Chapla A, et al.
JCEM case reports 2026; (4(1)):luaf286 doi:10.1210/jcemcr/luaf286.
PMID: 41356532
This page is for informational purposes only and does not constitute medical advice about Laurence-Moon syndrome or PNPLA6-related disorders. Your genetics, neurology, eye-care, and endocrine specialists should interpret your symptoms and decide what screening or treatment you need.